Rock Health snags seed funding

Rock Health, a San Francisco-based digital health accelerator, has received an undisclosed amount of seed funding, the company announced in a blog post on its site. Bessemer Venture Partners and Kaiser Permanente Ventures led the round with participation from KPCB, Montreux Equity Partners and Great Oaks Ventures. To read more details about the funding, visit here.

Epirus grabs $36 mln Series B funds and merges with Zalicus

Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that include Adage Capital, Greenwoods Investment, Gibralt US, Monashee Capital Partners, TPG Biotech, Montreux Equity Partners and 5AM Ventures. Also, Epirus will merge with Zalicus. No financial terms were disclosed. The merged entity will be led by Amit Munshi as president and CEO. Based in Boston, Epirus is a biopharmaceutical firm focused on biosimilar monoclonal antibodies while Zalicus specializes in developing new treatments for patients suffering from pain and inflammation.

Tobira Therapeutics Appoints Three Execs

Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from […]

RCP Acquired by ASA

Hollywood, Florida-based Renal CarePartners has been acquired by Ambulatory Services of America, nd its subsidiary, Innovative Dialysis Systems. Renal CarePartners currently owns interests in and manages 17 dialysis centers in eight states and the territory of Puerto Rico, providing care to approximately 1,100 patients. The company’s private equity sponsors are Montreux Equity Partners and Noro-Moseley […]

Pivot Medical Adds $32M Series C

Sunnyvale, Calif.-based Pivot Medical, which develops minimally invasive hip restoration technologies, has raised $32 million in Series C financing. Adams Street Partners, a new investor, led the round. New investor Delphi Ventures, founding investor Montreux Equity Partners, and existing investor Ivy Capital Partners also contributed.

SI-BONE Bags $16M Round

SI-BONE, the Calif.-based medical device company that treats the sacroiliac joint, received a $16 million round of funding that was led by Montreux Equity Partners in Menlo Park. Skyline Ventures also participated in the round. John Savarese, M.D., Managing Director at Montreux, will join the SI-BONE Board of Directors.

Tobira Therapeutics Names Andrew Hindman As President and Chief Executive

Tobira Therapeutics Inc. hired Andrew Hindman as president and chief executive officer. Hindman was Nodality Inc.’s senior vice president of corporate development.Tobira is a N.J.-based biopharmaceutical company that is focused on developing therapies for HIV infection. It is backed by Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.


peHUB Funding Opps: Afraxis, Brazen Careerist, GutCheck, More

peHUB readers tell me they’d like to learn more about potential funding opportunities that might not yet be in their deal pipeline. With that in mind, we’ve put together a list of companies that are still in the market, based on SEC filings and our own reporting.

Know about other companies that should be on this list? Let me know at [email protected] And if you’re on this list and have raised money since your last SEC filing, please shoot me an email so I can update readers.

Below this list, you’ll find another section about companies that have concluded their fundraising efforts…

Pulmonx Raises $32 Million

Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget